Commencing a new anti-obesity project designed to develop an oral medication to assist weight reduction and sustaining weight control in conjunction with other contemporary treatments and approaches. This project has now entered the pre-clinical phase with proof-of-concept animal studies underway.

GaRP is the working title for an evidence-based complementary medicine that has been designed to address the underlying factors associated with chronic gastrointestinal conditions such as IBS and IBD. It contains a special form of bromelain, an enzyme found in pineapple stems, along with other safe and recognised components. These ingredients, when combined and coated, have a positive impact on the lining of your digestive system. They also promote a healthy balance in the gut's ecosystem and its chemical byproducts, while allowing specific parts of your digestive tract to absorb these components effectively. GaRP's broad indications for use are based on strong pre-clinical IBD research with a focus on adjunctive treatment